CNS Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CNS Pharmaceuticals, Inc. (CNSP) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $12.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$4.25M, a 164.53% decline year-over-year.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $6.59M, a 2371.33% increase year-over-year.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $266.50K.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$4.94M, a 166.50% decline year-over-year.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $739.64K, a 87.49% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $5.91M.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$9.51M, a 288.22% decline from fiscal 2022.
- CNS Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $5.05M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $12.78M 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | -$4.25M 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $739.64K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $3.40M 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $5.67M 10-Q · filed 2026-08-12 | $5.67M 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $6.59M 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | $5.91M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $6.42M 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | $942.84K 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | $266.50K 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -$9.51M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$9.15M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$5.78M 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | -$4.94M 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | $5.05M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $2.02M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $3.95M 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $7.44M 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | -$9.03M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$5.71M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | -$7.15M 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | -$2.96M 10-Q · filed 2022-05-13 | ||||
| 2020-12-31 | $6.80M 10-K · filed 2022-03-03 | ||||
| 2020-09-30 | -$5.93M 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | -$4.62M 10-Q · filed 2021-08-13 | ||||
| 2020-03-31 | -$1.86M 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $6.69M 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | $344.38K 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | $626.19K 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | -$130.71K 10-Q · filed 2020-05-15 | ||||
| 2018-12-31 | $444.59K 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $598.08K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |